A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause

References

• Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med. 2005;118(Suppl 12B):14–24.
   PubMedGoogle Scholar
• Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006;96(7):1226–1235.
   PubMed Web of Science ®Google Scholar
• Williams RE, Kalilani L, DiBenedetti DB, et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007;58(4):348–358.
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7): 728–753.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A, et al. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Pinkerton J, Constantine G. Compounded non-FDA‒approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey. Menopause. 2016;23(4):359–367.
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Gill TK, Broadbent JL, et al. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric. 2009;12(2):122–130.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Fertil Steril. 2012;98(2):308–312.
   PubMed Web of Science ®Google Scholar
• Iftikhar S, Shuster LT, Johnson RE, et al. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt). 2011;20(4):559–565.
   PubMed Web of Science ®Google Scholar
• Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: A review. Menopause. 2004;11(3):356–367.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA takes action against compounded menopause hormone therapy drugs; [cited 2015 Aug 11]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116832.htm
   Google Scholar
• Bijuva^TM (estradiol and progesterone) capsules, for oral use Prescribing Information. Boca Raton, FL: TherapeuticsMD; 2018.
   Google Scholar
• Gaudard AM, Silva de Souza S, Puga ME, et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev. 2016;8:CD010407.
   PubMed Web of Science ®Google Scholar
• Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018;21(4):346–354.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–454.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;8(11):e78016.
   PubMed Web of Science ®Google Scholar
• Yang Z, Hu Y, Zhang J, et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017;33(2):87–92.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30(2):340–345.
   PubMed Web of Science ®Google Scholar
• Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488–493.
   PubMed Web of Science ®Google Scholar
• Sutton SS, Hardin JW, Bramley TJ, et al. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22(4):242–248.
   PubMed Web of Science ®Google Scholar
• Coca A, Agabiti-Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension. J Hypertens. 2017;35(8):1546–1553.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Bon C, Amadio JM, et al. Pharmacokinetics of the first combination 17beta-estradiol/progesterone capsule in clinical development for menopausal hormone therapy. Menopause. 2015;22(12):1308–1316.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Amadio JM, Bernick BA, et al. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Maturitas. 2015;81(1):28–35.
   PubMed Web of Science ®Google Scholar
• Prometrium® (Progesterone, USP) Prescribing Information. Catalent Pharma Solutions. St. Petersburg, FL; 2011.
   Google Scholar
• Lobo RA, Liu J, Stanczyk FZ, et al. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules). Menopause. 2019; 26(7):720–727.
   Web of Science ®Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2018;132(1):161–170.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Stanczyk FZ, Constantine G, et al. Progesterone bioavailability for preventing endometrial stimulation with a continuous-combined regimen of TX-001HR (oral estradiol and micronized progesterone capsules). Presented at IMS 16 World Congress on Menopause; 2018, June 6–9, 2018, Vancouver, Canada. Climacteric.
   Google Scholar
• Constantine GD, Revicki DA, Kagan R, et al. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms. Menopause. 2019;26(5):513–519.
   PubMed Web of Science ®Google Scholar
• Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24:161–175.
   PubMed Web of Science ®Google Scholar
• Spritzer KL, Hays RD MOS Sleep Scale: A manual for use and scoring; 2003 November.
   Google Scholar
• American College of Radiology. ACR practice parameter for the performance of ultrasound-guided precutaneous breast interventional procedures; 2016 [cited 2018 Jan 23]. Available from: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/US-GuidedBreast.pdf
   Google Scholar
• Simon JA, Kaunitz A, Kroll R, et al. Oral 17β-estradiol-progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause. 2019;26(5):506–512.
   PubMed Web of Science ®Google Scholar
• Kagan R, Constantine G, Kaunitz AM, et al. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause. 2019;26(6):622–628.
   Google Scholar
• US Department of Health and Human Services (FDA). Draft guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms–recommendations for clinical evaluation; January 2003. [cited 2018 Dec 21]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/informationbyDrugClass/UCM135338.pdf
   Google Scholar
• Archer DF, Pickar JH, Graham S, et al. Incidence of abnormal mammograms with oral, combined 17β-estradiol and progesterone capsules. Endocr Rev. 2018;39:2. Supplement 1.
   Google Scholar
• Lobo RA, Liu J, Kaunitz AM, et al. Effects of single-capsule 17β-estradiol/progesterone (TX-001HR) on metabolic parameters and cardiovascular outcomes in menopausal women of the REPLENISH trial. Menopause. 2018;25(12):1484–1485.
   Web of Science ®Google Scholar
• Archer DF, Pickar JH, Graham S, et al. Effects of single-capsule 17β-estradiol/progesterone (TX-001HR) on weight and blood pressure in menopausal women of the REPLENISH trial. Menopause. 2018;25(12):1496–1497.
   Web of Science ®Google Scholar
• Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust. 2007;187(4):244–245.
   PubMed Web of Science ®Google Scholar
• Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. Journal of Women's Health (Larchmt). 2014;23(8):642–648.
   PubMed Web of Science ®Google Scholar
• Dezman VL, Gersak MZ, Gersak K. 2015. Two case of atypical endometrial hyperplasia associated with “bioidentical” hormone replacement therapy: IGCS-0084 Uterine Cancer, including sarcoma. Int J Gynecol Cancer. 2015;25(Suppl 1):71.
   PubMedGoogle Scholar
• Climara Pro® (estradiol/Levonorgestrel transdermal system) Prescribing Information. 3M Drug Delivery Systems. Northridge, CA; 2007.
   Google Scholar
• CombiPatch® (estradiol/norethindrone acetate transdermal system) Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ; 2005.
   Google Scholar
• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273(3):199–208.
   PubMed Web of Science ®Google Scholar
• Monticciolo DL, Caplan LS. The American College of Radiology’s BI-RADS 3 classification in a nationwide screening program: current assessment and comparison with earlier use. Breast J. 2004;10(2):106–110.
   PubMedGoogle Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA. 2003;289(24):3243–3253.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER cancer statistics review 1975-2014; cancer of the female breast; [cited 2017 Jul 20]. Available from: https://seer.cancer.gov/csr/1975_2014/results_merged/sect_04_breast.pdf
   Google Scholar
• Banks E, Reeves G, Beral V, et al. Hormone replacement therapy and false positive recall in the million women study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res. 2006;8(1):R8.
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580.
   PubMed Web of Science ®Google Scholar
• Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174(1):25–31.
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, PY S. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2011;70(4):354–360.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med. 2004;164(5):482–484.
   PubMedGoogle Scholar
• Prempro™/Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets) Prescribing Information. Wyeth Pharmaceuticals Inc. Philadelphia, PA; 2008.
   Google Scholar
• Activella® (estradiol/norethindrone acetate) tablets. Novo Nordisk Inc. Princeton, NJ; 2006.
   Google Scholar
• Angeliq® (drospirenone and estradiol) tablets, for oral use Prescribing Information. Bayer Healthcare. Whippany, NJ; 2005.
   Google Scholar